Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Part of paid clinical trials in Los Angeles, California.

Sponsor
Affimed GmbH
Study ID
NCT05109442
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Advanced Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

Key Dates

Start date
Nov 19, 2021
Status verified
Aug 2025
Primary completion
Mar 6, 2025
Completion
Jun 11, 2025

Study Design

Enrollment
112 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Escalation Phase
    The Escalation phase will determine the MTD/RP2D of AFM24 in combination with atezolizumab. A traditional 3+3 design will be used to determine the RP2D.
  • Experimental: Expansion Phase
    The expansion phase will collect preliminary evidence of efficacy and further confirm the safety of AFM24 in combination with atezolizumab.

Primary Outcome Measure

Phase 1: Incidence of Dose Limiting Toxicities (DLTs) During Cycle 1 [ Time Frame: During cycle 1 (each cycle has 28 days) ]

Locations (3)

FacilityCityStateZIPSite coordinators
USC Norris Comprehensive Cancer CenterLos AngelesCalifornia90033-
University of Chicago Medical CenterChicagoIllinois60637-
Johns Hopkins UniversityBaltimoreMaryland21287-

Related coverage on Hipa.ai

Find similar trials in Los Angeles, CA

By research site
USC Norris Comprehensive Cancer Center· Los Angeles, CAUniversity of Chicago Medical Center· Chicago, ILJohns Hopkins University· Baltimore, MD

Related Studies